February 17, 2022
InSysBio announces its participation in Tau2022 Global Conference. Tau2022 is held virtually on February 22-23, 2022. InSysBio team presents a poster within its frames, namely:
Tatiana comments on the poster, "In the poster we try to anticipate brain dynamics of pathological tau deposits during gosuranemab treatment and predict how early therapy should be started for highest efficacy".
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | January 2021 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
| ||||
|
4
|
5
|
6
|
7
|
8
|
9
|
10
|
|
11
|
12
|
13
|
14
1.
14 Jan 2021 14:28
InSysBio to publish the new article on identifiability analysis in PLOS Computational Biology
[Moscow – 11.01.2021] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, has published its recent scientific research on identifiability in PLOS Computational Biology.
|
15
|
16
|
17
|
|
18
|
19
|
20
|
21
|
22
|
23
|
24
|
|
25
|
26
1.
26 Jan 2021 13:14
InSysBio to announce the upgrade of its SbmlViewer application to version 0.2.7
[Moscow – 26.01.2021] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launces the new version of its SbmlViewer open project. Generally, SbmlViewer represents a tool for fast and easy reading of biological models written in SBML format.
|
27
|
28
|
29
|
30
|
31
|
Thank you for your message! We will get back to you shortly.
